Skip to main content
Biotest AG logo

Biotest AG — Investor Relations & Filings

Ticker · BIO3 ISIN · DE0005227201 LEI · 529900JVX7RPXBLYUD89 F Manufacturing
Open in API
Filings indexed 1,148 across all filing types
Latest filing 2023-04-28 Earnings Release
Country DE Germany
Listing F BIO3

About Biotest AG

https://www.biotest.com/de/en/index.cfm

Biotest AG is a global company that develops, manufactures, and supplies plasma protein products and biotherapeutic drugs. Sourced from human blood plasma, its products are primarily used in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. The portfolio includes immunoglobulins (e.g., Intratect), coagulation factors, and albumins designed to treat severe and chronic diseases such as immune deficiencies, haemophilia, and coagulation disorders. The company manages the entire value chain from clinical development to sales and is advancing a pipeline of new treatments, including next-generation immunoglobulins (BT595) and fibrinogen concentrates (BT524). Biotest also provides Human Serum Albumin for use as a multifunctional excipient in pharmaceutical and diagnostic applications.

Recent filings

Filing Released Lang Actions
Biotest AG: Biotest and Grifols further strengthen their cooperation - EBIT forecast 2023 significantly raised
Earnings Release Classification · 100% confidence The document is explicitly labeled as an "Ad-hoc" notice and an "Inside information acc. to Article 17 MAR". It announces a significant operational and financial update (strengthening cooperation with Grifols and raising the EBIT forecast for 2023). This type of immediate, material disclosure required under EU Market Abuse Regulation (MAR) for listed companies does not fit neatly into the standard periodic reports (10-K, IR) or specific event reports (DIV, DIRS, etc.). While it contains financial guidance changes, it is primarily a regulatory disclosure of material, non-public information. Given the options, the most appropriate general category for an immediate, non-standard regulatory announcement that doesn't fit elsewhere is 'Regulatory Filings' (RNS), as it is a mandatory disclosure under EU rules transmitted via a news service (EQS). It is not an Earnings Release (ER) which typically covers actual past results, nor is it a Call Transcript (CT) or Investor Presentation (IP). FY 2023
2023-04-28 English
Biotest AG: Biotest AG opens 12th plasma collection centre in Hungary
Regulatory Filings Classification · 100% confidence The document is a press release dated April 25, 2023, announcing a specific operational update: the opening of a new plasma collection center in Hungary. It is not a comprehensive financial report (like 10-K or IR), an earnings release (ER), or a formal regulatory filing like a proxy statement or director's dealing report. It is a general corporate announcement regarding business operations and expansion. Since it doesn't fit into the highly specific categories like AGM-R, 10-K, ER, or DIV, and it is a standard corporate news item disseminated via EQS News, the most appropriate classification is the general regulatory/corporate announcement fallback category, RNS (Regulatory Filings), as it serves as a general disclosure to the market.
2023-04-25 English
Biotest AG: Biotest AG opens 10th plasma collection centre in Germany
Regulatory Filings Classification · 100% confidence The document is a short press release dated April 20, 2023, announcing a specific operational update: the opening of Biotest AG's 10th plasma collection center in Germany. It contains key highlights, contact information, and boilerplate legal disclaimers, but it is not a comprehensive financial report (like 10-K or IR) nor is it a transcript (CT). It is a general corporate announcement distributed via EQS News. Since it is a specific, non-financial operational update that doesn't fit the other specific categories (like DIRS, DIV, CAP, etc.), the most appropriate classification is the general regulatory announcement/news category, RNS, as per the definition of a general regulatory announcement or fallback category.
2023-04-20 English
Biotest Aktiengesellschaft: Bekanntmachung der Einberufung zur Hauptversammlung am 09.05.2023 in Frankfurt am Main mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information Classification · 100% confidence The document is explicitly titled 'Einladung zur ordentlichen Hauptversammlung 2023' (Invitation to the Annual General Meeting 2023) and details the agenda ('TAGESORDNUNG') for this meeting, which includes voting on management discharge, auditor election, and remuneration report approval. The text also mentions the date and location of the AGM (May 9, 2023, in Frankfurt am Main) and is issued under German corporate law (§121 AktG). This clearly identifies the document as material related to the Annual General Meeting.
2023-03-31 German
Biotest AG: Biotest achieves important milestone in phase III trial in acquired fibrinogen deficiency
Regulatory Filings Classification · 99% confidence The document is a press release dated March 30, 2023, announcing a clinical trial milestone for Biotest AG regarding their fibrinogen concentrate BT524. It details the successful interim analysis of the phase III trial 'AdFIrst' and provides context on the disease, market potential, and future regulatory steps. This type of announcement, focusing on clinical trial progress and operational updates rather than comprehensive financial results (like a 10-K or IR) or management changes (MANG), is best classified as a general corporate announcement. Since it is not a formal regulatory filing like a 10-K, nor a specific financial report, and it is not merely announcing the publication of another report (RPA), it falls under the general category for corporate news releases that don't fit elsewhere, which is Regulatory Filings (RNS) as per the provided definitions, often used for press releases disseminated via services like EQS News.
2023-03-30 English
Biotest AG: Biotest core business profitable at Euro 60.7 million
Earnings Release Classification · 100% confidence The document is a press release dated March 23, 2023, summarizing the financial results for the financial year 2022 ('Biotest core business profitable at Euro 60.7 million', 'In the financial year 2022, the Biotest Group slightly increased its sales revenue to € 516.1 million'). It provides key financial metrics (Sales, EBIT, adjusted EBIT) and an outlook for 2023. This content aligns perfectly with an Earnings Release (ER), which is the initial announcement of periodical financial results (key highlights only). Although it mentions the 'Annual Report 2022 is available on the company’s website', the document itself is the announcement of those results, not the full report (10-K) or the management discussion/analysis (MDA). It is too detailed for just a Report Publication Announcement (RPA) and contains specific financial figures, making ER the best fit. FY 2022
2023-03-23 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.